93 results
8-K
EX-99.1
AKBA
Akebia Therapeutics Inc.
27 Mar 24
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
8:35pm
by stating, “Anemia is a debilitating condition that significantly impacts our daily lives. It is promising to see the introduction of innovative treatment … experience and by leveraging its relationship with CSL Vifor, an industry leader in bringing innovative therapies to U.S. dialysis organizations. In line
8-K
EX-99.1
AKBA
Akebia Therapeutics Inc.
14 Mar 24
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
4:18pm
dedicated to delivering an innovative oral therapeutic treatment for anemia due to chronic kidney disease for patients on dialysis.”
Fourth Quarter 2023
8-K
EX-99.1
l9586jve jd
25 May 23
Entry into a Material Definitive Agreement
8:05am
DEFA14A
z08dt0mp7n wah1v
21 Apr 23
Additional proxy soliciting materials
4:30pm
8-K
EX-99.1
aao15pajrve61v8b c4
22 Feb 22
Akebia Therapeutics Announces Amendment of License Agreement with Vifor Pharma in Preparation for Potential Vadadustat Launch
8:35am
8-K
EX-99.1
w4zszi
9 Sep 21
Regulation FD Disclosure
6:13am